NCT03998891

Brief Summary

Patients with heart failure (HF) have an amelioration in clinical outcomes during a restricted dietary salt intake. To date, they experienced an amelioration of functional New York Association Heart (NYHA) class, reduction of hospital admissions, and mortality, in a percentage about 60%. However, these data have been not investigated in CRTd patients with HF under a condition of restricted vs. normal dietary salt intake. In the present study authors will evaluate clinical outcomes in patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d) and restricted dietary salt intake (group 1) in addition to conventional heart failure (HF) therapy vs. CRTd patients under conventional dietary salt intake and conventional HF therapy (group 2). The study will be conducted during a 12-months of follow-up, to evaluate the prognosis of CRTd patients treated with restricted (n 271) vs. a matched cohort of CRTd patients treated with normal salt dietary intake in addition to conventional HF therapy (n 288). Authors' opinion is that, restricted salt intake in addition to conventional HF therapy might significantly reduce body weight and heart chambers volumes in CRTd patients, leading to a significant improvement of ejection fraction and of the 6 minutes walking test (6MWT), and to a reduction of the arrhythmic burden. Consequently, restricted salt intake in addition to conventional HF therapy might reduce hospital admissions for heart failure worsening.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

June 21, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 26, 2019

Completed
Last Updated

June 26, 2019

Status Verified

June 1, 2019

Enrollment Period

4.4 years

First QC Date

June 21, 2019

Last Update Submit

June 25, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants with heart failure worsening events

    Authors will report by telephonic interviews, clinical visits and hospital discharge schedules the patients with HF worsening events.

    12 months

Study Arms (2)

salt restricted diet

In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.

Other: restricted dietary salt intake

normal salt diet

In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.

Interventions

These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.

salt restricted diet

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A population of patients affected by a stable and chronic heart failure in NYHA 2-3 class, and under optimal and full medical anti-HF therapy. These patients treated with CRTd will be aged between 18 and 75 years.

You may qualify if:

  • heart failure in NYHA 2-3 class;
  • patients under optimal and full medical therapy for HF;
  • patients treated with CRTd;
  • patients without neoplastic diseases;
  • patients without inflammatory sistemic diseases.

You may not qualify if:

  • decompensated HF;
  • unstable HF;
  • patients without full anti-HF medical therapy;
  • patients without indication to receive CRTd;
  • patients with renal failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Raffaele Marfella

Naples, 80138, Italy

Location

MeSH Terms

Conditions

Heart FailureEdema

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

June 21, 2019

First Posted

June 26, 2019

Study Start

January 1, 2013

Primary Completion

June 1, 2017

Study Completion

January 1, 2018

Last Updated

June 26, 2019

Record last verified: 2019-06

Locations